Abstract:Safely and efficiently controlling gene expression is a long-standing goal of biomedical research, and the recently discovered bacterial CRISPR/Cas system can be harnessed to create powerful tools for epigenetic editing. Current state-of-the-art systems consist of a deactivated-Cas9 nuclease (dCas9) fused to epigenetic effector motifs/domains, along with a guide RNA (gRNA) which defines the genomic target. Such systems have been used to safely and effectively silence or activate a specific gene target under a variety of circumstances. Adeno-associated virus (AAV) vectors are the therapeutic platform of choice for delivery of genetic cargoes; nevertheless, their small packaging capacity is not suitable for the delivery of large constructs, including most CRISPR/dCas9-effector systems. To circumvent this, many AAV-based CRISPR/Cas tools are delivered separately from two viral cassettes. However, this approach requires higher viral payloads and usually is less efficient. Here we develop a compact dCas9-based repressor system packaged within a single, optimized AAV vector. The system uses a smaller dCas9 variant derived from Staphylococcus aureus (Sa). A novel repressor was engineered by fusing the small transcription repression domain (TRD) from MeCP2 with the KRAB repression domain. The final dSaCas9-KRAB-MeCP2(TRD) construct can be efficiently packaged, along with its associated gRNA, into AAV particles. Using reporter assays, we demonstrate that the platform is capable of robustly and sustainably repressing the expression of multiple genes-of-interest, both in vitro and in vivo. Most relevantly, we successfully silenced APOE, the primary genetic risk factor for late onset Alzheimer disease (LOAD). This new platform will broaden the CRISPR/dCas9 toolset available for transcriptional manipulation of gene expression in research and therapeutic settings.

Applying gene‐editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer’s disease

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders

The Molecular Efficacy of CRISPR-Cas9 in TreatingAlzheimer’s Disease

Prevention and Treatment of Alzheimer's Disease Through CRISPR/Cas Technology

CRISPR/Cas9 Mechanism and Applications Progression

Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases

Precision Gene Editing Strategies with CRISPR-Cas9 for Advancing Cancer Immunotherapy and Alzheimer's Disease

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

High-throughput CRISPRi and CRISPRa technologies in 3D genome regulation for neuropsychiatric diseases

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders

Development and application of CRISPR/Cas9 technologies in genomic editing.

Application of novel CRISPR tools in brain therapy

The Application of CRISPR/Cas9 Technology in Neurological Diseases

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Vector enabled CRISPR gene editing – A revolutionary strategy for targeting the diversity of brain pathologies

Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease

Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies

Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice

Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease

Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy